Glox Therapeutics secures £4.3m seed funding to combat AMR

16th November 2023 Uncategorised 0

The bacteriocin development programme will first target pseudomonas aeruginosa

More: Glox Therapeutics secures £4.3m seed funding to combat AMR
Source: News